Skip to main content

From the Helm: CSL’s David Lamont on the biotech giant’s bright future

Jessica Amir
February 20, 2020

In the latest instalment of Bell Direct’s From the Helm series, Jess has a chat with CSL’s CFO David Lamont.

David gives the inside scoop on CSL, the market leader in the blood plasma and vaccine market. Additionally, he explains CSL’s own products, programmes and partnerships, and the steps taken by the medical giant to tackle coronavirus.

Plus, he sheds some light on the unique situation the broader pharmaceuticals industry finds itself in when it comes to new competition, as well as CSL’s future proofing strategy.

Morning Bell 22 February

Sam Kanaan
February 22, 2024

Morning Bell 21 February

Grady Wulff
February 21, 2024

Morning Bell 20 February

Grady Wulff
February 20, 2024

Morning Bell 19 February

Grady Wulff
February 19, 2024

Weekly Wrap 16 February

Sophia Mavridis
February 16, 2024

Morning Bell 16 February

Sam Kanaan
February 16, 2024

Morning Bell 15 February

Sam Kanaan
February 15, 2024

Morning Bell 14 February

Sam Kanaan
February 14, 2024

Morning Bell 13 February

Grady Wulff
February 13, 2024